Etoricoxib
Pharmaceutical Premium
Pharmaceutical API

Etoricoxib

High-purity pharmaceutical grade Etoricoxib manufactured to meet stringent USP/EP specifications for pharmaceutical formulations and research applications. Our pharmaceutical grade material delivers exceptional purity and consistency for critical pharmaceutical manufacturing.

  • USP/EP Grade Specifications
  • High Purity (≥99.0%)
  • Comprehensive Analytical Testing
  • Regulatory Compliance Documentation
  • Pharmaceutical Manufacturing Grade
  • Quality Assurance Certified
Request Quote Technical Support

Technical Specifications

Chemical Formula: C18H15ClN2O2S
CAS Number: 202409-33-4
Molecular Weight: 358.85 g/mol
Purity (HPLC): ≥99.0% (pharmaceutical grade)
Physical State: White to off-white crystalline powder
Water Content (Karl Fischer): ≤0.5%
Residue on Ignition: ≤0.1%
Heavy Metals (as Pb): ≤10 ppm
Related Substances: ≤1.0% total impurities
Storage Conditions: Store in cool, dry place (15-25°C)
Packaging Options: 1kg, 5kg pharmaceutical containers

Applications

NSAID Drug Manufacturing
Arthritis Treatment Formulations
Pain Management Products
API Synthesis & Development
Anti-inflammatory Research
Pharmaceutical Research
Drug Product Manufacturing
Quality Control Testing
Regulatory Compliance
Clinical Trial Materials
Bioanalytical Method Development
Reference Standard Applications

Industry-Specific Grades

DRAVYOM offers specialized Etoricoxib grades tailored for specific pharmaceutical requirements, ensuring optimal performance and regulatory compliance across diverse NSAID and pain management drug manufacturing applications.

USP Grade (Pharmaceutical)
Purity: ≥99.0% (HPLC) Water Content: ≤0.5% Heavy Metals: ≤10 ppm Application: Pharmaceutical formulations
EP Grade (European Pharmacopoeia)
Purity: ≥99.0% (pharmaceutical) Related Substances: ≤1.0% Residue on Ignition: ≤0.1% Application: European market compliance
Research Grade
Purity: ≥98.0% (analytical) Water Content: ≤1.0% Particle Size: Controlled Application: R&D, method development
GMP Grade
Purity: ≥99.5% (pharmaceutical) Endotoxins: ≤2.5 EU/mg Microbial Limits: Compliant Application: NSAID formulations

Quality Standards

DRAVYOM's pharmaceutical grade Etoricoxib is manufactured under stringent cGMP protocols, meeting international pharmaceutical standards including USP, EP, and ICH guidelines. Our pharmaceutical-grade production ensures consistent quality and regulatory compliance.

cGMP Certified Manufacturing
USP/EP Grade Specifications
≥99.0% Pharmaceutical Purity
Advanced Analytical Testing
Ultra-Low Impurities
Batch-to-Batch Consistency
Traceable Certificate of Analysis
Temperature-Controlled Logistics

Advanced Chemical Properties & Performance

Pharmaceutical grade Etoricoxib exhibits exceptional chemical properties essential for NSAID applications. Its ultra-pure composition and precise molecular structure ensure reliable performance in demanding pharmaceutical formulations and research applications.

Analytical Properties
Solubility (Water): Slightly soluble
LogP (octanol/water): 2.06
pKa: 4.7
Molecular Weight: 358.84 g/mol
Physical Properties
Appearance: White to off-white crystalline powder
Melting Point: 135-137°C
Bulk Density: 0.4-0.6 g/mL
Hygroscopicity: Non-hygroscopic
Pharmaceutical Performance
Bioavailability: 100% (oral)
Protein Binding: >92%
Half-life: 22 hours
Mechanism: Selective COX-2 inhibitor
Purity Specifications
Assay (HPLC): ≥99.0%
Related Substances: ≤1.0% total
Water Content: ≤1.0% (Karl Fischer)
Residue on Ignition: ≤0.2%
Stability Properties
Shelf Life: 3 years (unopened)
Light Sensitivity: Protect from light
Temperature Stability: Store below 25°C
pH Stability: Stable in neutral conditions

Performance Characteristics

Detailed performance metrics demonstrate pharmaceutical grade Etoricoxib superiority in NSAID applications with exceptional COX-2 selectivity, anti-inflammatory efficacy, and reproducibility across diverse therapeutic protocols.

COX-2 Selectivity

High selectivity for COX-2 enzyme

Reduced GI side effects
Anti-inflammatory

Potent anti-inflammatory activity

Effective pain relief
Stability Profile

Chemical stability: Excellent under storage conditions

Maintains potency for 3 years
Thermal Stability

Melting point: 135-137°C

Stable during pharmaceutical processing
Batch Reproducibility

Variation: ±0.1% between batches

Consistent therapeutic efficacy
Long Half-life

Extended duration of action (22 hours)

Once-daily dosing

Safety Information

Pharmaceutical ingredient requiring professional handling protocols. Well-established safety profile for NSAID therapy applications. Handle with appropriate pharmaceutical-grade safety precautions and ensure proper GMP environmental controls. Clinical monitoring for cardiovascular and renal effects during therapeutic use.

Pharmaceutical Grade
Professional Use
Monitor cardiovascular effects

Storage & Handling

Store in original containers in a cool, dry, well-ventilated area away from moisture and light. Keep containers tightly closed and maintain pharmaceutical-grade environmental controls. Use appropriate GMP handling techniques for API processing.

Cool storage (15-25°C)
Protect from moisture
Protect from light
GMP handling required

Chemical Mechanisms & Reaction Pathways

Etoricoxib exhibits selective COX-2 inhibition properties through specific enzyme binding, providing anti-inflammatory, analgesic, and antipyretic effects for osteoarthritis, rheumatoid arthritis, and acute pain management.

Selective COX-2 Inhibition

Highly selective cyclooxygenase-2 enzyme inhibition

Reduced gastrointestinal side effects
Anti-inflammatory Action

Blocks prostaglandin synthesis and inflammatory cascade

Effective inflammation control
Analgesic Properties

Provides effective pain relief through central mechanisms

Comprehensive pain management
Once-Daily Dosing

Long half-life enabling convenient once-daily administration

Improved patient compliance

Regulatory Compliance & Documentation

Comprehensive regulatory compliance ensures anti-inflammatory pharmaceutical manufacturing access with complete documentation packages supporting international standards and NSAID development.

USP Standards

United States Pharmacopeia anti-inflammatory drug specifications

EP Monograph

European Pharmacopoeia specifications for selective COX-2 inhibitors

NSAID GMP

Specialized GMP for anti-inflammatory drug manufacturing

ICH Guidelines

International anti-inflammatory drug development regulatory compliance

NSAID DMF

Drug Master File for anti-inflammatory applications

Safety Documentation

Comprehensive anti-inflammatory safety and pharmacovigilance documentation

Technical Support & Value-Added Services

DRAVYOM's anti-inflammatory pharmaceutical team provides comprehensive formulation support, stability testing, and regulatory services for Etoricoxib NSAID applications.

NSAID Formulation
  • Anti-inflammatory formulation optimization
  • Tablet and capsule development
  • Bioavailability enhancement
  • Custom NSAID development
Analytical Services
  • API purity and potency analysis
  • Anti-inflammatory impurity profiling
  • Stability testing protocols
  • Method validation support
Regulatory Support
  • NSAID regulatory filing
  • DMF preparation and maintenance
  • International compliance guidance
  • NSAID pharmacovigilance
Supply Solutions
  • Anti-inflammatory supply chain
  • Custom packaging solutions
  • Global distribution network
  • Emergency NSAID supply

Environmental Impact & Sustainability

Our Etoricoxib production emphasizes environmental responsibility through sustainable anti-inflammatory manufacturing practices, waste minimization, and comprehensive environmental impact management.

Green Chemistry

Environmentally friendly synthesis and processing methods

Water Conservation

Advanced water treatment and recycling systems

Clean Production

Energy-efficient pharmaceutical manufacturing processes

Waste Reduction

Comprehensive pharmaceutical waste management protocols

ISO 14001

Environmental management system certified production

Sustainable Sourcing

Responsible procurement of pharmaceutical raw materials

Manufacturing Excellence & Quality Control

DRAVYOM's pharmaceutical manufacturing facility employs advanced synthesis technology and continuous monitoring systems to ensure consistent Etoricoxib quality and anti-inflammatory therapeutic performance.

Pharmaceutical GMP

Advanced manufacturing in controlled clean-room environment

Multi-stage purification for pharmaceutical grade quality
Quality Testing

Comprehensive testing including assay, impurities, and stability

HPLC verification and anti-inflammatory analysis
Quality Systems

ISO 9001:2015 quality management with pharmaceutical compliance

Continuous improvement and pharmaceutical validation
Pharmaceutical Packaging

Pharmaceutical-grade containers with moisture protection

Stability protection and contamination prevention

Market Applications & Performance Data

Comprehensive anti-inflammatory data demonstrating Etoricoxib effectiveness in arthritis and pain management with quantified performance metrics and clinical validation data.

Anti-inflammatory Formulations
Bioavailability: >80% oral bioavailability Stability: 3-year shelf life validated Compatibility: Excellent with tablet excipients
Therapeutic Applications
Arthritis: Proven osteoarthritis and rheumatoid arthritis relief Pain Management: Effective acute and chronic pain relief Safety: Selective COX-2 inhibition profile
Manufacturing Performance
Yield: 96% pharmaceutical grade recovery Purity: >99.5% pharmaceutical specification Consistency: 99.8% batch-to-batch reproducibility

DRAVYOM Competitive Advantages

Anti-inflammatory Excellence

Superior pharmaceutical grade with proven COX-2 selectivity and regulatory compliance

Reliable Supply

Guaranteed anti-inflammatory supply with strategic inventory management

NSAID Expertise

Dedicated anti-inflammatory development team with specialized formulation support

Regulatory Compliance

Complete anti-inflammatory documentation with DMF support and international compliance

Global Standards

International pharmaceutical compliance with USP, EP, and ICH guidelines

Partnership Approach

Collaborative anti-inflammatory relationships with specialized development services